Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction

Objective

To assess the safety and tolerability of NR in patients with Stage C heart failure with reduced ejection fraction (HFrEF).

Study Design

Randomized, double-blind, placebo-controlled study in 30 patients with Stage C HFrEF

Dose

2000 mg

Duration

12 weeks

Key Outcomes

  • High-dose NR supplementation was safe and well-tolerated, significantly, and dose-dependently (nearly) doubled whole blood NAD+ levels, and increased PBMC mitochondrial respiration.

  • 'NR also decreased expression of inflammatory markers, such as NLRP3.

Clinical, Cardiovascular HealthANAD StaffCardiovascular Health